title: Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.
abstract: Within the past 10 years, treatment and diagnostic guidelines for nontuberculous mycobacteria have been recommended by the American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA). Moreover, the Clinical and Laboratory Standards Institute (CLSI) has published and recently (in 2011) updated recommendations including suggested antimicrobial and susceptibility breakpoints. The CLSI has also recommended the broth microdilution method as the gold standard for laboratories performing antimicrobial susceptibility testing of nontuberculous mycobacteria. This article reviews the laboratory, diagnostic, and treatment guidelines together with established and probable drug resistance mechanisms of the nontuberculous mycobacteria.
authors: Department of Microbiology, The University of Texas Health Science Center at Tyler, USA. barbara.elliott@uthct.edu
authors: Barbara A
authors: BA
authors: Brown-Elliott
authors: Kevin A
authors: KA
authors: Nash
authors: Richard J
authors: RJ
authors: Wallace
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001842:Bone and Bones / Q000382:microbiology; D002473:Cell Wall / Q000187:drug effects; D017291:Clarithromycin / Q000494:pharmacology; D024881:Drug Resistance, Bacterial; D006801:Humans; D008826:Microbial Sensitivity Tests / Q000592:standards; D009165:Mycobacterium Infections, Nontuberculous / Q000188:drug therapy* / Q000382:microbiology; D009170:Nontuberculous Mycobacteria / Q000187:drug effects / Q000302:isolation & purification / Q000472:pathogenicity*; D017410:Practice Guidelines as Topic; D012015:Reference Standards; D015203:Reproducibility of Results; D012307:Risk Factors
chemical_list: D000900:Anti-Bacterial Agents; D017291:Clarithromycin